NSC 14613

CAS No. 91396-88-2

NSC 14613( NSC 14613 | N’-phenyl-hydrazine-Isonicotinic acid )

Catalog No. M16567 CAS No. 91396-88-2

PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 32 In Stock
5MG 29 In Stock
10MG 49 In Stock
25MG 80 In Stock
50MG 113 In Stock
100MG 166 In Stock
200MG 235 In Stock
500MG 395 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    NSC 14613
  • Note
    Research use only, not for human use.
  • Brief Description
    PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.
  • Description
    PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.
  • In Vitro
    PluriSIn 1, a small-molecule inhibitor of stearoyl-coA desaturase (SCD), on induced pluripotent stem cells (iPS)-derived cardiomyocytes (CM). PluriSIn 1 treatment significantly decreases the mRNA and protein level of Nanog, a marker for both cell pluripotency and tumor progression; importantly, we provide evidence that PluriSIn 1 treatment at 20 μM for 1 day significantly induces the apoptosis of Nanog-positive iPS derivates (iPSD). In addition, PluriSIn 1 treatment at 20 μM for 4 days diminished Nanog-positive stem cells in cultured iPSD while not increasing apoptosis of iPS-derived CM. To investigate whether PluriSIn 1 treatment prevents tumorigenicity of iPSD after cell transplantation, we intramyocardially injected PluriSIn 1- or DMSO-treated iPSD in a mouse model of myocardial infarction (MI). DMSO-treated iPSD readily formed Nanog-expressing tumors 2 weeks after injection, which is prevented by treatment with PluriSIn 1. Moreover, treatment with PluriSIn 1 does not change the expression of cTnI, α-MHC, or MLC-2v, markers of cardiac differentiation (P>0.05, n=4). Importantly, PluriSIn 1-treated iPS-derived CM exhibits the ability to engraft and survive in the infarcted myocardium.
  • In Vivo
    ——
  • Synonyms
    NSC 14613 | N’-phenyl-hydrazine-Isonicotinic acid
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    SCD
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    91396-88-2
  • Formula Weight
    213.24
  • Molecular Formula
    C12H11N3O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 43 mg/mL (201.65 mM)
  • SMILES
    O=C(NNC1=CC=CC=C1)C2=CC=NC=C2
  • Chemical Name
    N'-phenylisonicotinohydrazide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ben-David U, et al. Cell Stem Cell, 2013, 12(2), 167-179.
molnova catalog
related products
  • Manitimus

    Manitimus (FK778) is an inhibitor of dehydroorotate dehydrogenase and an immunosuppressant with immunosuppressive and antiproliferative activity.

  • DSM265

    DSM265 (PfSPZ) is a dihydroorotic acid dehydrogenase inhibitor with antimalarial activity (IC50: 8.9 nM).DSM265 inhibits the growth of Pf3D7 parasites and can be used for the treatment and prophylaxis of malaria infections.

  • CB29

    CB29 is a specific inhibitor of aldehyde dehydrogenase 3A1 (ALDH3A1).